Cargando…

The Exposure of Breast Cancer Cells to Fulvestrant and Tamoxifen Modulates Cell Migration Differently

There is no doubt that there are increased benefits of hormonal therapy to breast cancer patients; however, current evidence suggests that estrogen receptor (ER) blockage using antiestrogens is associated with a small induction of invasiveness in vitro. The mechanism by which epithelial tumor cells...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lymperatou, Dionysia, Giannopoulou, Efstathia, Koutras, Angelos K., Kalofonos, Haralabos P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3713599/ https://www.ncbi.nlm.nih.gov/pubmed/23936773 http://dx.doi.org/10.1155/2013/147514

Ejemplares similares

Adhesion strength and anti-tumor agents regulate vinculin of breast cancer cells
por: Metsiou, Despoina Nektaria, et al.
Publicado: (2022)

Antiproliferative effect of exemestane in lung cancer cells
por: Koutras, Angelos, et al.
Publicado: (2009)

Role of SUMOylation in differential ERα transcriptional repression by tamoxifen and fulvestrant in breast cancer cells
por: Traboulsi, Tatiana, et al.
Publicado: (2018)

Resistance to hormone therapy in breast cancer cells promotes autophagy and EGFR signaling pathway
por: Siatis, Konstantinos E., et al.
Publicado: (2023)

MiR-214 increases the sensitivity of breast cancer cells to tamoxifen and fulvestrant through inhibition of autophagy
por: Yu, Xinfeng, et al.
Publicado: (2015)

RANK-C Expression Sensitizes ER-Negative, EGFR-Positive Breast Cancer Cells to EGFR-Tyrosine Kinase Inhibitors (TKIs)
por: Sirinian, Chaido, et al.
Publicado: (2021)

Epidermal growth factor receptor status and Notch inhibition in non-small cell lung cancer cells
por: Giannopoulou, Efstathia, et al.
Publicado: (2015)

Correction to: Identification of novel human RANK isoforms generated through alternative splicing. Implications in breast cancer cell survival and migration
por: Papanastasiou, Anastasios D., et al.
Publicado: (2018)

Identification of a seasonal pattern to brain metastases
por: Sakellakis, Minas, et al.
Publicado: (2016)

Tamoxifen and fulvestrant induced steatohepatitis with cirrhosis: A rare case report
por: Roy, Somnath, et al.
Publicado: (2019)

Identification of novel human receptor activator of nuclear factor-kB isoforms generated through alternative splicing: implications in breast cancer cell survival and migration
por: Papanastasiou, Anastasios D, et al.
Publicado: (2012)

Comparative study and meta-analysis of meta-analysis studies for the correlation of genomic markers with early cancer detection
por: Lanara, Zoi, et al.
Publicado: (2013)

PIOS (Patras Immunotherapy Score) Score Is Associated with Best Overall Response, Progression-Free Survival, and Post-Immunotherapy Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) Treated with Anti-Program Cell Death-1 (PD-1) Inhibitors
por: Dimitrakopoulos, Foteinos-Ioannis, et al.
Publicado: (2020)

Mechanical Loading-Related Bone Gain Is Enhanced by Tamoxifen but Unaffected by Fulvestrant in Female Mice
por: Sugiyama, Toshihiro, et al.
Publicado: (2010)

Small Extracellular Vesicles (sEVs) Biogenesis Molecular Players Are Associated with Clinical Outcome of Colorectal Cancer Patients
por: Kottorou, Anastasia, et al.
Publicado: (2023)

Exceptional response to nivolumab of a heavily pre-treated patient with metastatic renal-cell cancer: from a case report to molecular investigation and future perspectives
por: Dimitrakopoulos, Foteinos-Ioannis D., et al.
Publicado: (2020)

Immune checkpoint inhibitor-induced musculoskeletal manifestations. A multicentre prospective study
por: Daoussis, Dimitrios, et al.
Publicado: (2020)

Palbociclib and Fulvestrant Act in Synergy to Modulate Central Carbon Metabolism in Breast Cancer Cells
por: Warth, Benedikt, et al.
Publicado: (2019)

Genetic Variations of CD40 and LTβR Genes Are Associated With Increased Susceptibility and Clinical Outcome of Non-Small-Cell Carcinoma Patients
por: Dimitrakopoulos, Foteinos-Ioannis D., et al.
Publicado: (2021)

Characterization and Biological Evaluation of Propolis from Poland
por: Popova, Milena, et al.
Publicado: (2017)

NF-κB2 and RELB offer prognostic information in colorectal cancer and NFKB2 rs7897947 represents a genetic risk factor for disease development
por: Antonacopoulou, Anna, et al.
Publicado: (2020)

Fulvestrant inhibits growth of triple negative breast cancer and synergizes with tamoxifen in ERα positive breast cancer by up-regulation of ERβ
por: Mishra, Ameet K., et al.
Publicado: (2016)

A Review of Fulvestrant in Breast Cancer
por: Nathan, Mark R., et al.
Publicado: (2017)

Analysis of RANK-c interaction partners identifies TRAF3 as a critical regulator of breast cancer aggressiveness
por: Sirinian, Chaido, et al.
Publicado: (2022)

Expression of Immune System-Related Membrane Receptors CD40, RANK, BAFFR and LTβR is Associated with Clinical Outcome of Operated Non-Small-Cell Lung Cancer Patients
por: Dimitrakopoulos, Foteinos-Ioannis D., et al.
Publicado: (2019)

Economic Evaluation for Palbociclib Plus Fulvestrant vs Ribociclib Plus Fulvestrant and Abemaciclib Plus Fulvestrant in Endocrine-Resistant Advanced or Metastatic Breast Cancer in Italy
por: Colombo, Giorgio Lorenzo, et al.
Publicado: (2023)

The Antiestrogens Tamoxifen and Fulvestrant Abolish Estrogenic Impacts of 17α-ethinylestradiol on Male Calling Behavior of Xenopus laevis
por: Hoffmann, Frauke, et al.
Publicado: (2012)

Serglycin Is Implicated in the Promotion of Aggressive Phenotype of Breast Cancer Cells
por: Korpetinou, Angeliki, et al.
Publicado: (2013)

Identification of the Significant Genes Regulated by Estrogen Receptor in Estrogen Receptor-Positive Breast Cancer and Their Expression Pattern Changes When Tamoxifen or Fulvestrant Resistance Occurs
por: Cheng, Ran, et al.
Publicado: (2020)

Retrospective Evaluation of Fulvestrant Efficacy and Clinical Results in Patients Using Fulvestrant
por: Kut, Engin, et al.
Publicado: (2023)

Iris Metastasis in a Patient With Small Cell Lung Cancer: A Case Report
por: Sakellakis, Minas, et al.
Publicado: (2016)

ERβ1 Sensitizes and ERβ2 Desensitizes ERα-Positive Breast Cancer Cells to the Inhibitory Effects of Tamoxifen, Fulvestrant and Their Combination with All-Trans Retinoic Acid
por: Meligova, Aggeliki K., et al.
Publicado: (2023)

Fulvestrant: pharmacokinetics and pharmacology
por: Robertson, J F R, et al.
Publicado: (2004)

Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor–Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial
por: Schmid, Peter, et al.
Publicado: (2019)

Fulvestrant and the sequential endocrine cascade for advanced breast cancer
por: Johnston, S
Publicado: (2004)

Oestradiol measurement during fulvestrant treatment for breast cancer
por: Owen, Laura J., et al.
Publicado: (2019)

NF-kB2 Genetic Variations are Significantly Associated with Non-Small Cell Lung Cancer Risk and Overall Survival
por: Dimitrakopoulos, Foteinos-Ioannis D., et al.
Publicado: (2018)

Resuming Sensitivity of Tamoxifen-Resistant Breast Cancer Cells to Tamoxifen by Tetrandrine
por: Wang, Yuntao, et al.
Publicado: (2021)

RF05 | PSUN341 Role of sirtuins in breast cancer cells response to Fulvestrant
por: Sengupta, Surojeet, et al.
Publicado: (2022)

Fulvestrant in advanced breast cancer: evidence to date and place in therapy
por: Boér, Katalin
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_0t6t1vrb0u0p2863mfarmnkfjt